Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Aug 30 · below the Ichimoku cloud · RSI 37 · MACD above its signal · 4% above its 52-week low
None of the 29 investors followed here reported a position in 0853.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 0853.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 8.2 | -7.1 | -13.3 | -8.1 | -13.7 | -18.0 | 8.9 | -9.6 | 0.0 | 0.0 | −44.2% | ||
| 2025 | 2.4 | 14.8 | 7.0 | -11.7 | 4.7 | 18.9 | 62.3 | -14.8 | 13.9 | -12.2 | -7.4 | -2.9 | +71.6% |
| 2024 | -31.5 | 33.1 | -14.5 | -4.3 | -7.8 | -9.1 | 1.5 | -7.7 | 59.5 | -18.3 | -6.7 | 5.5 | −24.7% |
| 2023 | 19.2 | -9.4 | -16.8 | -6.4 | -22.0 | 5.0 | 10.0 | -13.9 | -11.8 | 3.9 | 1.8 | -32.7 | −59.0% |
| 2022 | -21.8 | -2.7 | -17.7 | -11.2 | -1.5 | 46.4 | -18.5 | -15.2 | -14.0 | 22.6 | 10.3 | 12.4 | −27.6% |
| 2021 | 29.5 | -15.9 | -4.2 | 28.2 | 15.7 | 7.3 | -15.9 | -17.8 | -8.8 | -16.4 | -11.2 | -12.9 | −32.2% |
| 2020 | -7.6 | 28.0 | 60.6 | -3.8 | 32.7 | 39.3 | 20.5 | -6.2 | -12.8 | -11.4 | 22.8 | 25.3 | +354.0% |
| 2019 | -2.2 | -7.8 | 6.3 | 0.0 | -15.2 | -7.3 | 14.3 | 4.8 | 2.2 | 13.7 | -8.6 | 25.1 | +19.9% |
| 2018 | 9.0 | -5.8 | 9.8 | 7.9 | 16.6 | -11.4 | -4.5 | 9.5 | 4.5 | -9.7 | -8.1 | -10.5 | +2.0% |
| 2017 | -1.0 | 0.3 | -4.7 | -2.0 | 3.3 | 9.8 | 0.2 | 13.5 | 3.0 | 6.9 | 16.9 | -16.1 | +29.3% |
| 2016 | -1.1 | -14.8 | 8.3 | 19.5 | -3.5 | -0.5 | 8.2 | 17.9 | 2.6 | 13.0 | 1.2 | 0.5 | +57.8% |
| 2015 | 2.8 | 3.6 | 11.5 | 11.9 | 1.8 | -13.6 | -14.9 | -12.6 | 8.1 | 5.5 | -5.9 | 21.3 | +13.1% |
| 2014 | -1.4 | 10.8 | -3.4 | -1.9 | 1.1 | -5.8 | -6.8 | -3.9 | -16.7 | 5.1 | -2.3 | -14.6 | −35.5% |
| 2013 | 24.6 | -4.1 | 5.3 | -3.5 | 25.9 | 5.3 | -4.9 | -17.3 | -7.0 | 9.8 | 2.3 | -5.8 | +24.6% |
| 2012 | 2.9 | 3.8 | -11.0 | 0.5 | -7.1 | -3.2 | 0.3 | -3.0 | 20.3 | 3.4 | 15.1 | -11.1 | +6.3% |
| 2011 | -16.9 | -12.1 | 0.9 | 4.2 | 1.2 | -13.3 | -7.2 | -16.6 | 5.7 | 8.0 | -6.8 | -7.3 | −48.5% |
| 2010 | -8.7 | -5.1 | -0.8 | −14.0% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jan 11, 2026 | Chen, Jonathan WDivisional Officer | Conversion at price 0.45 per share. | 100K | $44.66K |
| Jan 11, 2026 | Chen, Jonathan WDivisional Officer | Sale at price 1.47 per share. | 100K | $147.31K |
| Jan 7, 2026 | Chen, Jonathan WDivisional Officer | Conversion at price 0.45 per share. | 560K | $250.21K |
| Jan 7, 2026 | Chen, Jonathan WDivisional Officer | Sale at price 1.50 per share. | 560K | $837.26K |
| Jan 6, 2026 | Chen, Jonathan WDivisional Officer | Conversion at price 0.45 per share. | 400K | $178.84K |
| Jan 6, 2026 | Chen, Jonathan WDivisional Officer | Sale at price 1.48 per share. | 400K | $591.24K |
| Aug 27, 2025 | Chen, Jonathan WDivisional Officer | Acquisition at price 0.69 per share. | 800K | $549.68K |
MicroPort Scientific Corporation, together with its subsidiaries, engages in the innovating, manufacturing, and marketing medical devices globally in the People's Republic of China, the United States of America, Europe, Middle East and Africa, Japan, and internationally. The company's Cardiovascular Devices segment offers medical solutions for the treatment of coronary artery-related diseases; and coronary stents, related delivery systems, balloon catheters, accessories, and active devices. Its Orthopedics Devices segment provides reconstructive joints, spine and trauma products, and other professional implants and instruments. The company's Cardiac Rhythm Management Business segment offers defibrillators, cardiac resynchronization therapy devices, and pacemakers. Its Endovascular and Peripheral Vascular Devices segment provides disease solutions for the interventional treatment of thoracic and abdominal aortic aneurysm, peripheral vascular diseases, aortic dissection aneurysms, and other arteriovenous related diseases. The company's Neurovascular Devices segment offers neurovascular therapeutic and access devices for cerebrovascular diseases. The company's Surgical Robot Business segment offers surgical robots comprising robot ontology, control algorithm, electrical engineering, image-based navigation, and precision imaging. Its Structural Heart Disease Business segment provides heart valve devices. It is also involved in the distribution of medical devices. MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai, the People's Republic of China.
Buy / hold / sell counts
No recent headlines.